Our data suggest that IGF2BP3 overexpression identifies a subset of pancreatic ductal adenocarcinomas with an extremely poor outcome and supports the rationale for developing therapies to target the IGF pathway in this cancer. The gene discussed is IGF1; the disease is pancreatic ductal adenocarcinoma.